The Longest Review: Inside Ovation’s Wait For Sabril
This article was originally published in The Pink Sheet Daily
Executive Summary
The anticonvulsant vigabatrin is one of a dozen products for which FDA has missed user fee deadlines so far this year. Fifteen years after the NDA first was submitted, maybe that shouldn’t be a surprise.
You may also be interested in...
Ovation’s Sabril Visual Defect Is Topic Of FDA Meeting; Is End To Longest Review In Sight?
FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will evaluate vigabatrin for two epilepsy indications at a meeting rescheduled for Jan. 7-8.
Ovation’s Sabril Visual Defect Is Topic Of FDA Meeting; Is End To Longest Review In Sight?
FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will evaluate vigabatrin for two epilepsy indications at a meeting rescheduled for Jan. 7-8.
Takeda’s Alogliptin Falls Prey To FDA Slowdown
Delay is no bellwether for oral anti-diabetic drugs, the firm says.